AstraZeneca demonstrates 83% risk reduction for long-acting Covid-19 antibody at 6-month analysis – Endpoints News
AstraZeneca demonstrates 83% risk reduction for long-acting Covid-19 antibody at 6-month analysis – Endpoints News

AstraZeneca demonstrates 83% risk reduction for long-acting Covid-19 antibody at 6-month analysis – Endpoints News

As the founders of the Covid-19 vaccine application at the FDA, Novavax tried to excite investors on Wednesday with its experimental combination of Covid / influenza injection. But the data remains early, and comments from the FDA are reportedly painting a difficult road to authorization.

The biotechnology revealed the first results from its Phase I / II study, which looked at the two-stranded vaccine, and said that the observed immune responses were similar to those produced by each of its independent shoots. As such, Novavax says it plans to launch a “Phase II verification trial” before the end of the year.

Continue reading Endpoints with a free subscription

Unlock this story right away and join 139,800+ biopharmacists who read Endpoints daily – and for free.


Leave a Reply

Your email address will not be published.